Análise do perfil imunológico e citohistológico durante a transmissão vertical de Trypanosoma cruzi em diferentes estágios da infecção experimental

Trypanosma cruzi is the causative agent of Chagas disease. This trypanosomiasis has become a global public health problem due to migration of Latin Americans to non-endemic countries. In Latin America with the succesful implementation of control domiciliated vector infestation and blood transfusion, the importance of congenital transmission has recently increased. Considering the tight regulation of immune system during gestation, we aimed to investigate the changes in the immune system caused by T.cruzi infection in the gestation outcome. T cruzi G and Y strain were used to infect female BALB/c mice before or after mating with non-infected male mice. The presence of vaginal plug was used as indicative of mating. Females were euthanized 8 days after confirmation of vaginal plug. We used three female control groups, only infected, only infected and non-infected and non-pregnant females. Two groups were infected before mating and other two were infected 4 days after confirmation of vaginal plug. The uterus and spleen were collected to immunochemistry, qPCR, immunofluorescence and cytokine analysis. Our results showed that despite the MMP’s identification being similarly among groups, T.cruzi higher virulent strain can impaire gestation outcome prior mating; the infection also increased cytokines like IFN-γ, IL-1β and IL-4; and leucocytes in uterine environment was altered, responding locally to systemic changes caused by T.cruzi infection. In conclusion this work suggests that T.cruzi infection can impaire gestation outcome and local response to sistemic infection was able to control the infection allowing pregnancy development in some conditions.

Atividade antiangiogênica da forma recombinante da proteína 21 de Trypanosoma cruzi

Chagas disease, caused by the parasite Trypanosoma cruzi, is the cause of Chronic chagasic cardiomyopathy (CCC). The prospection of innovative therapeutic agents against CCC is a major task. The recombinant form of 21 (rP21), a secreted T. cruzi protein involved in host cell invasion and on progression of chronic inflammatory processes have been studied as a potential novel therapeutic target. Our present work aimed to verify and investigate the impact of rP21 in the formation of blood vessels in vitro and in vivo. First, tEnd cells were treated with different concentrations of rP21 or bacterial extract and viability and cellular adhesion were evaluated by MTT and angiogenesis inhibition by Matrigel tube formation assay and murine model. To verify the proteolytic activity of rP21 on extracellular matrix (ECM) components, fibrinogen, matrigel and fibronectin was incubated with rP21 or not. In addition, we performed proliferation assays and cell cycle analysis. Furthermore, the accumulation and distribution of F-actin was determined by Phalloidin staining using ImageJ software. Finally, tEnd cells were incubated with rP21 and the mRNA levels were analyzed by real-time PCR. Our results showed that rP21 did not alter cell viability and adhesion, but strongly inhibited vessel formation in vitro and in vivo. Tube formation assay showed that angiogenesis inhibition was dependent of the CXCR4-rP21 binding. In addition to these results, we observed that the rP21 was able to inhibit cell proliferation and promoted a significant reduction in the number of 4n cells (G2/M phase). Moreover, we found that rP21 significantly increased F-actin levels and this protein was able to modulate expression of genes related to angiogenesis and actin cytoskeleton. However, rP21 showed no significant activity on the matrix components. In this sense, we conclude that the rP21-endothelial cells (ECs) interaction via CXCR4 promotes inhibition of vessel formation through a cascade of intracellular events, such as inhibition of ECs proliferation and modulation of the expression of molecules associated with angiogenic processes and actin cytoskeleton.

O uso da PCR em tempo real para o estudo da carga parasitária e dos níveis transcricionais durante a infecção experimental por Trypanosoma cruzi

Trypanosoma cruzi is causative agent of Chagas disease, one of most neglected tropical diseases. Estimated that about 11 million people worldwide are infected by T. cruzi and about 6 to 7 million people are at risk in endemic areas. During the process of invasion of host and parasite interact enabling signal transduction and gene expression modulation in response to invasion. The diversity of activated proteins and pathways to repair the damage by disruption of the plasma membrane interest to us and thus present study developed a new form of detection and quantitation by polymerase chain reaction in real time (qPCR) of parasitic load T. cruzi and quantified transcriptional levels relative (RT-qPCR) of dysferlin, Sphingomyelin acid esferase (ASM), transcription factor EB (TFEB) Galectins 1 and 3 and Annexin A2. This study demonstrated that quantification by real time PCR using primers P21fw and P21rv was specific and sensitive for detection of T. cruzi in vivo and in vitro, as well as transcriptional levels of genes related to cytoskeletal organization and repair plasma membrane are modulated in response to damage generated by parasite.

Detecção parasitológica e molecular de tripanossomatídeos em triatomíneos sinantrópicos e primatas neotropicais no Brasil central

Tese (doutorado)—Universidade de Brasília, Faculdade de Medicina, Programa de Pós-Graduação em Medicina Tropical, 2016.

Análise proteômica de células não fagocíticas na fase inicial da infecção por trypanosoma cruzi

Dissertação (mestrado)—Universidade de Brasília, Faculdade de Medicina, Programa de Pós-Graduação em Patologia Molecular, 2015.

Dinâmica das integrações de minicírculos de kDNA de Trypanosoma Cruzi no genoma hospedeiro

Dissertação (mestrado)—Universidade de Brasília, Faculdade de Medicina, Programa de Pós-Graduação em Patologia Molecular, 2016.

Aceitação sensorial da bebida açaí batido após tratamento térmico dos frutos.

O açaí (Euterpe oleracea Mart.) é uma fruta nativa da floresta amazônica tendo seu consumo mundial impulsionado devido à presença de antocianinas e sua capacidade antioxidante (1,2). O mercado consumidor interno regional amazônico, bastante tradicional e peculiar, tem preferência pelo produto processado sem qualquer tratamento térmico e para consumo imediato (3). No Brasil, este tipo de bebida tem sido relacionado a casos crescentes de doença de Chagas (4), devido à contaminação dos frutos pelo protozoário Trypanosoma cruzi (5), agente causal da doença, podendo ser inativado pelo tratamento térmico por branqueamento dos frutos a 80 °C por 10s. Entretanto, o fruto de açaí também apresenta elevada carga microbiana patogênica que quando não tratada adequadamente é repassada para o produto final (6). Outra importante fonte de contaminação microbiológica da bebida é a água utilizada durante todas as operações de processamento, pois mais de 50% dos municípios localizados na região amazônica brasileira não realizam a cloração simples da água (7). Um aspecto importante a ser considerado é que o tipo de processamento, mesmo melhorando a qualidade microbiológica, não pode interferir no perfil qualitativo sensorial do produto e influenciar na aceitabilidade pelo consumidor tradicional de açaí batido. Neste sentido, este trabalho propôs estudar o impacto sensorial de alternativas térmicas eficazes como tratamentos de sanitização de frutos de açaí, que fossem factíveis de implementação para o processador artesanal, e que seu produto fosse aceitável para o consumidor tradicional.

Epidemiologia e controle das doenças transmissíveis no Brasil

Na década de 1930, as doenças transmissíveis foram a principal causa de morte nas capitais do Brasil. As melhorias sanitárias, o desenvolvimento de novas tecnologias, como as vacinas e os antibióticos, a ampliação do acesso aos serviços de saúde e as medidas de controle fizeram com que esse quadro se modificasse bastante até os dias de hoje. Porém, mesmo diante dos notórios avanços obtidos para controlar essas doenças, elas ainda se constituem como importante problema de saúde pública no país. Fatores de ordem biológica, geográfica, ecológica, social, cultural e econômica atuam simultaneamente na produção, distribuição e controle das doenças. O controle de doenças vetoriais, tais como: doença de Chagas, malária, leishmanioses, esquistossomose, febre amarela e dengue, depende de ações conjuntas de todos os níveis de atenção à saúde. Diante disso, este material foca em como a equipe de atenção básica pode atuar no controle e combate dessas doenças.

Cuidados em doenças infecciosas e parasitárias: endêmicas, emergentes e re-emergentes

Este módulo é dividido em nove lições e aborda epidemiologia, manifestações clínicas, diagnóstico, tratamento, medidas de controle e vigilância epidemiológica das seguintes doenças: Influenza, Febre Amarela, Leishmaniose, Malária, Doença de Chagas, Parasitoses, Esquistossomose, Doenças Sexualmente Transmissíveis e Hantavirose.

Doenças transmissíveis: epidemiologia e controle

Na década de 1930, as doenças transmissíveis foram a principal causa de morte nas capitais do Brasil. As melhorias sanitárias, o desenvolvimento de novas tecnologias, como as vacinas e os antibióticos, a ampliação do acesso aos serviços de saúde e as medidas de controle fizeram com que esse quadro se modificasse bastante até os dias de hoje. Porém, mesmo diante dos notórios avanços obtidos para controlar essas doenças, elas ainda se constituem como importante problema de saúde pública no país. Fatores de ordem biológica, geográfica, ecológica, social, cultural e econômica atuam simultaneamente na produção, distribuição e controle das doenças. O controle de doenças vetoriais, tais como: doença de Chagas, malária, leishmanioses, esquistossomose, febre amarela e dengue, depende de ações conjuntas de todos os níveis de atenção à saúde. Diante disso, este material foca em como a equipe de atenção básica pode atuar no controle e combate dessas doenças.

Aminoquinolone WR6026 as a feasible substitute for gentian violet in Chagas' disease prophylaxis in preserved blood for transfusional purposes

The search for a colorless, nontoxic and efficient drug to prevent transfusion-associated Chagas' disease (TACD) has been underway unsuccessfully since 1953 when gentian violet was preconized and to date is still being used as the only in vitro trypanocidal agent. The recent findings of aminoquinolone "WR6026" as a trypanocidal agent, led the authors to study the metabolism of red cells stored with this compound, the main objective of which was to define its applicability in TACD control. Ten units of human whole blood collected in CPDA-1 were divided into two equal satellite bags. One had "WR6026" (final concentration 62.5µg/mL) added and the other was used as a control, both were stored at 4ºC. At baseline, day 7, 14, 21 and 28, samples were taken for the following measurements: adenosine triphosphate (ATP), hemoglobin, electrolytes (sodium and potassium), gases (pO2 and pCO2) and osmotic fragility. The results of tests and control were analyzed through parametric t-student test. The results were similar in both groups throughout the experiment except for the level of ATP on day 14, which presented significantly higher values in the tests when compared with the controls (p = 0.012). It was concluded that WR6026 does not interfere in the preservation and probably the viability of the erythrocytes also until day 28 of storage. Consequently the authors suggest that WR6026 could emerge as a colorless substitute for gentian violet in the control of TACD in endemic areas.

Chagas infection transmission control: situation of transfusional transmission in Brazil and other countries of Latin America

The transmission of the transfusion-associated Chagas disease is an important mechanism of its dissemination in several Latin American countries. The transmission risk depends on five factors: prevalence of infection in blood donors, degree of serological coverage, sensibility of used tests, safety of obtained results and infection risk. The Southern Cone Iniciative set off by the Pan-American Health Organization, in 1991, is contributing to the implementation of blood law in each endemic country, and to reduce the risk of transfusional transmission of this horrible disease. Despite the clear improvement of Brasilian hemotherapy after 1980 (with the creation of the Blood National Program - Pró-Sangue) and the significant reduction of the chagasic infection among its blood donors; socio-economic, politic and cultural unlevels, prevent it from reaching the necessary universality and security. In order to assure both, the Brazilian Ministry of Health decided to restructure its blood system. In May, 1998, a great program was launched, to reach a specific goal: Blood - 100% with quality safety in all its process until 2003. It was divided in 12 projects, intends to guarantee the quality and self sufficiency in blood and hemoderivates.

Chagas disease: current epidemiological trends after the interruption of vectorial and transfusional transmission in the Southern Cone countries

Chagas disease, named after Carlos Chagas who first described it in 1909, exists only on the American Continent. It is caused by a parasite, Trypanosoma cruzi, transmitted to humans by blood-sucking triatomine bugs and by blood transfusion. Chagas disease has two successive phases, acute and chronic. The acute phase lasts 6 to 8 weeks. After several years of starting the chronic phase, 20% to 35% of the infected individuals, depending on the geographical area will develop irreversible lesions of the autonomous nervous system in the heart, esophagus, colon and the peripheral nervous system. Data on the prevalence and distribution of Chagas disease improved in quality during the 1980's as a result of the demographically representative cross-sectional studies carried out in countries where accurate information was not available. A group of experts met in Brasília in 1979 and devised standard protocols to carry out countrywide prevalence studies on human T. cruzi infection and triatomine house infestation. Thanks to a coordinated multi-country program in the Southern Cone countries the transmission of Chagas disease by vectors and by blood transfusion has been interrupted in Uruguay in1997, in Chile in 1999, and in 8 of the 12 endemic states of Brazil in 2000 and so the incidence of new infections by T. cruzi in the whole continent has decreased by 70%. Similar control multi-country initiatives have been launched in the Andean countries and in Central America and rapid progress has been recorded to ensure the interruption of the transmission of Chagas disease by 2005 as requested by a Resolution of the World Health Assembly approved in 1998. The cost-benefit analysis of the investments of the vector control program in Brazil indicate that there are savings of US$17 in medical care and disabilities for each dollar spent on prevention, showing that the program is a health investment with good return. Since the inception in 1979 of the Steering Committee on Chagas Disease of the Special Program for Research and Training in Tropical Diseases of the World Health Organization (TDR), the objective was set to promote and finance research aimed at the development of new methods and tools to control this disease. The well known research institutions in Latin America were the key elements of a world wide network of laboratories that received - on a competitive basis - financial support for projects in line with the priorities established. It is presented the time line of the different milestones that were answering successively and logically the outstanding scientific questions identified by the Scientific Working Group in 1978 and that influenced the development and industrial production of practical solutions for diagnosis of the infection and disease control.